-
1 Comment
Mallinckrodt plc is currently in a long term downtrend where the price is trading 99.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Mallinckrodt plc's total revenue sank by 6.1% to $698M since the same quarter in the previous year.
Its net income has increased by 17518.2% to $192M since the same quarter in the previous year.
Finally, its free cash flow grew by 149.3% to $59M since the same quarter in the previous year.
Based on the above factors, Mallinckrodt plc gets an overall score of 3/5.
| Exchange | NYSE MKT |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | nan |
|---|---|
| Market Cap | 5M |
| PE Ratio | None |
| Target Price | 1.75 |
| Dividend Yield | 0.0% |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Dublin, Ireland. On August 28, 2023, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MNK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
